Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation

참고문헌 (91)

1. Ferro JM, "Cardioembolic stroke: an update", Lancet Neurol, 2, pp.177~188 (2003)
2. Arboix A, "Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis", Curr Cardiol Rev, 6, pp.150~ (2010)
3. Eriksson S-E, "Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study", Cerebrovasc Dis, 12, pp.171~180 (2001)
4. Kolominsky-Rabas PL, "Epidemiology of ischemic stroke subtypes according to toast criteria incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study", Stroke, 32, pp.2735~2740 (2001)
5. Ferro JM, "Brain embolism", J Neurol, 250, pp.139~147 (2003)
6. Weir N, "An update on cardioembolic stroke", Postgrad Med J, 84, pp.133~142 (2008)
7. Arboix A, "Cardioembolic infarction in the sagrat cor‐alianza hospital of barcelona stroke registry", Acta Neurol Scand, 96, pp.407~412 (1997)
8. Bogousslavsky J, "The lausanne stroke registry: analysis of 1,000 consecutive patients with first stroke", Stroke, 19, pp.1083~1092 (1988)
9. Timsit S, "Brain infarction severity differs according to cardiac or arterial embolic source", Neurology, 43, pp.728~733 (1993)
10. Al-Rajeh S, "Stroke in a tertiary hospital in saudi arabia: a study of 372 cases", Eur Neurol, 31, pp.251~256 (1991)
11. Rothrock JF, "An analysis of ischemic stroke in an urban southern California population. The University of California, San Diego, Stroke Data Bank", Arch Intern Med, 153, pp.619~624 (1993)
12. Norrving B, "Epidemiology of stroke in Lund‐Orup, Sweden, 1983-85", Acta Neurol Scand, 78, pp.408~413 (1988)
13. Jung KH, "Secular trends in ischemic stroke characteristics in a rapidly developed country results from the Korean Stroke Registry Study (secular trends in Korean stroke)", Circ Cardiovasc Qual Outcomes, 5, pp.327~334 (2012)
14. Hong KS, "Stroke statistics in Korea: Part I. Epidemiology and risk factors: a report from the Korean Stroke Society and Clinical Research Center for Stroke", J Stroke, 15, pp.2~20 (2013)
15. Han SW, "Frequency and significance of cardiac sources of embolism in the toast classification", Cerebrovasc Dis, 24, pp.463~468 (2007)
16. Page RL, "Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia", Circulation, 89, pp.224~227 (1994)
17. Strickberger SA, "Relationship between atrial tachyarrhythmias and symptoms", Heart Rhythm, 2, pp.125~131 (2005)
18. Hart RG, "Current status of stroke risk stratification in patients with atrial fibrillation", Stroke, 40, pp.2607~2610 (2009)
19. Wolf PA, "Atrial fibrillation as an independent risk factor for stroke: The Framingham Study", Stroke, 22, pp.983~988 (1991)
20. Roger VL, "Heart disease and stroke statistics--2012 update: a report from the American Heart association", Circulation, 125, pp.2~220 (2012)
21. Wang TJ, "A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community", JAMA, 290, pp.1049~1056 (2003)
22. Go AS, "Prevalence of diagnosed atrial fibrillation in adults", JAMA, 285, pp.2370~2375 (2001)
23. Murphy NF, "A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland", Heart, 93, pp.606~612 (2007)
24. Heeringa J, "Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam Study", Eur Heart J, 27, pp.949~953 (2006)
25. Jeong Joon Hoon, "Prevalence of and Risk Factors for Atrial Fibrillation in Korean Adults Older than 40 Years", Journal of Korean Medical Science, 20(1), pp.26~ (2005), 대한의학회
26. Fuster V, "ACC", AHA, American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation), pp.Circulation, 2006[DOI]
27. Frost L, "Incident stroke after discharge from the hospital with a diagnosis of atrial fibrillation", Am J Med, 108, pp.36~40 (2000)
28. Frost L, "Age and risk of stroke in atrial fibrillation: evidence for guidelines?", Neuroepidemiol, 28, pp.109~115 (2007)
29. Gage BF, "Validation of clinical classification schemes for predicting stroke", JAMA, 285, pp.2864~2870 (2001)
30. Lip GY, "Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation", Chest, 137, pp.263~272 (2010)
31. Pisters R, "A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey", Chest, 138, pp.1093~1100 (2010)
32. Camm AJ, "Guidelines for the management of atrial fibrillation the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)", Eur Heart J, 31, pp.2369~2429 (2010)
33. Lee SH, "Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage", Neurology, 72, pp.171~176 (2009)
34. Lovelock CE, "Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies", Stroke, 41, pp.1222~1228 (2010)
35. Aguilar M, "Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks", Cochrane Database Syst Rev, 18, pp.006186~ (2007)
36. Aguilar M, "Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks", Cochrane Database Syst Rev, 20, pp.001927~ (2005)
37. Hylek EM, "Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation", N Eng J Med, 349, pp.1019~1026 (2003)
38. O’Donnell M, "Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study", Lancet Neurol, 5, pp.749~754 (2006)
39. Ay H, "Admission international normalized ratio and acute infarct volume in ischemic stroke", Ann Neurol, 64, pp.499~506 (2008)
40. Agarwal S, "Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis", Arch Intern Med, 172, pp.623~631 (2012)
41. Paciaroni M, "Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention", Atherosclerosis, 212, pp.564~566 (2010)
42. Albertsen IE, "Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis", Stroke, 44, pp.1329~1336 (2013)
43. 김도형, "Impact of CHADS 2 Score on Neurological Severity and Long-Term Outcome in Atrial Fibrillation-Related Ischemic Stroke", Journal of Clinical Neurology, 8(4), pp.251~258 (2012), 대한신경과학회
44. Hong H, "Early neurological outcomes according to CHADS2 score in stroke patients with non‐valvular atrial fibrillation", Eur J Neurol, 19, pp.284~290 (2012)
45. Lin PJ, "Reviewing the reality: why we need to change", Eur Heart J, 7, pp.15~20 (2005)
46. Oake N, "Frequency of adverse events in patients with poor anticoagulation: a meta-analysis", CMAJ, 176, pp.1589~1594 (2007)
47. Ahrens I, "New oral anticoagulant drugs in cardiovascular disease", Arch Intern Med emost, 104, pp.49~60 (2010)
48. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Eng J Med, 361, pp.1139~1151 (2009)
49. Gran ger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Eng J Med, 365, pp.981~992 (2011)
50. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Eng J Med, 365, pp.883~891 (2011)
51. Pengo V, "Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation", Thromb Haemost, 108, pp.65~73 (2012)
52. Wallentin L, "Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial", Lancet, 376, pp.975~983 (2010)
53. Cotton BA, "Acutely injured patients on dabigatran", Thromb Haemost, 365, pp.2039~2040 (2011)
54. Hori M, "Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation", Stroke, 44, pp.1891~1896 (2013)
55. Karthikeyan G, "Dabigatran: ready for prime time", Pol Arch Med Wewn, 120, pp.137~142 (2010)
56. Hohnloser SH, "Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial", Circulation, 125, pp.669~676 (2012)
57. Uchino K, "Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials", Arch Intern Med, 172, pp.397~402 (2012)
58. Hankey GJ, "Dabigatran etexilate", Circulation, 123, pp.1436~1450 (2011)
59. van Ryn J, "Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity", Thromb Haemost, 103, pp.1116~1127 (2010)
60. Kubitza D, "Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects", J Clin Pharmacol, 46, pp.549~558 (2006)
61. Hori M, "Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment", Circ J, 77, pp.632~638 (2013)
62. Perzborn E, "Rivaroxaban: a new oral factor xa inhibitor", Arterioscler Thrombo Vasc Biol, 30, pp.376~381 (2010)
63. Wong PC, "Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor", J Thromb Thrombolysis, 31, pp.478~492 (2011)
64. Raghavan N, "Apixaban metabolism and pharmacokinetics after oral administration to humans", Drug Metab Dispos, 37, pp.74~81 (2009)
65. Ezekowitz MD, "Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran", Am Heart J, 157, pp.805~810 (2009)
66. Schulman S, "Extended use of dabigatran, warfarin, or placebo in venous thromboembolism", N Eng J Med, 368, pp.709~718 (2013)
67. Stangier J, "Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate", Clin Pharmacokinet, 49, pp.259~268 (2010)
68. Stangier J, "The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects", Br J Clin Pharmacol, 64, pp.292~303 (2007)
69. Huisman MV, "Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice", Thromb Haemost, 107, pp.838~847 (2012)
70. Turpie AG, "Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor", Thromb Haemost, 108, pp.876~886 (2012)
71. Schulman S, "How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch", Blood, 119, pp.3016~3023 (2012)
72. Fleming TR, "Evaluating rivaroxaban for nonvalvular atrial fibrillatio--regulatory considerations", N Eng J Med, 365, pp.1557~1559 (2011)
73. Samama MM, "Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor", Thromb Haemost, 103, pp.815~825 (2010)
74. Mahtani KR, "Optimal loading dose of warfarin for the initiation of oral anticoagulation", Cochrane Database Syst Rev, 12, pp.008685~ (2012)
75. Sick PB, "Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation", J Am Coll Cardiol, 49, pp.1490~1495 (2007)
76. Stone D, "Early results with the LARIAT device for left atrial appendage exclusion in patients with atrial fibrillation at high risk for stroke and anticoagulation", Catheter Cardiovasc Interv (2013)[DOI]
77. Bartus K, "Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience", J Am Coll Cardiol, 62, pp.108~118 (2013)
78. Holmes DR, "Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial", Lancet, 374, pp.534~542 (2009)
79. Reddy VY, "Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial", Circulation, 127, pp.720~729 (2013)
80. Van Gelder IC, "A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation", N Eng J Med, 347, pp.1834~1840 (2002)
81. Opolski G, "Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study", Chest, 126, pp.476~486 (2004)
82. Sherman DG, "Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study", Arch Intern Med, 165, pp.1185~1191 (2005)
83. de Denus S, "Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis", Arch Intern Med, 165, pp.258~262 (2005)
84. Kumana CR, "Rhythm vs. rate control of atrial fibrillation meta‐analysed by number needed to treat", Br J Clin Pharmacol, 60, pp.347~354 (2005)
85. Caldeira D, "Rate vs rhythm control in patients with atrial fibrillation and heart failure: a systematic review and meta-analysis of randomised controlled trials", Eur J Intern Med, 22, pp.448~455 (2011)
86. Connolly SJ, "Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation", atrial flutter, 2009, pp.120, 1174~1180
87. Connolly SJ, "Dronedarone in high-risk permanent atrial fibrillation", N Eng J Med, 365, pp.2268~2276 (2011)
88. Tsadok MA, "Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation", Circulation, 126, pp.2680~2687 (2012)
89. Guyatt GH, "Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141, pp.7~47 (2012)
90. Lip GY, "The new NICE guideline on atrial fibrillation management", Heart, 93, pp.23~ (2007)
91. "Clinical Research Center for Stroke. Clinical Practice Guidelines for Stroke. 2013. ISBN: 978-89-94181-19-6"[URL]

관련 논문AI추천